TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06561048: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anapla

Sponsor: Corvus Pharmaceuticals, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT06561048 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06561048 Rescue Dossier →